Creatine 2-Year Trial: BMD Unchanged, but Femoral Bone Geometry Improved in Postmenopausal Women

Creatine has been a standard exercise supplement for over 30 years, but its impact on postmenopausal women’s bone density and muscle mass has been an under-studied domain. Two 2-year randomized trials emerging together in 2026 have begun clarifying when and how creatine helps menopausal women.

Canadian RCT: 237 participants, 2 years

The largest, published in Medicine & Science in Sports & Exercise, was a 237-participant 2-year RCT in Canada. Postmenopausal women were randomized into two groups: creatine monohydrate 0.1g/kg/day (~6g/day at 60kg) plus 3x weekly supervised resistance training, or placebo plus the same exercise.

Key results.

• Femoral BMD: no significant difference between groups
• Spinal BMD: no difference
• Proximal femur bone geometry: significantly improved in creatine group
• Strength (leg press, bench press): 10-15 percentage points greater improvement in creatine group
• Body composition (muscle mass): greater increase in creatine group

BMD itself didn’t change, but improvements in cross-sectional area, thickness, and bending strength of the proximal femur are clinically meaningful. Fractures are determined not by BMD alone but by bone geometry and muscle strength together.

Brazilian RCT: no effect in osteoporotic women

Another 2-year trial published the same year in Brazil targeted postmenopausal women diagnosed with osteopenia or osteoporosis. Results differ.

• BMD: no change
• Muscle mass and strength: no significant difference
• Daily living function: no difference

Two interpretive variables. First, the participants’ bone status may have progressed past creatine’s stimulation threshold. Second, the difference in exercise intensity and supervision; the Canadian trial standardized 3x weekly supervised resistance training, while the Brazilian protocol was less rigorous.

Exercise co-administration as the decisive variable

The combined message is clear. Creatine alone has minimal-to-no effect on postmenopausal bone health. Effect emerges through combination with resistance training, with exercise intensity and consistency as the deciding factors.

This matches creatine’s mechanism. It accelerates ATP regeneration in muscle cells, enabling higher-intensity short-burst exercise. Exercise mechanically stimulates bone, and creatine amplifies that stimulus. Without exercise, there is no stimulus to amplify, and bone effects don’t materialize.

Who benefits

Patterns from combined trial data.

• Clear benefit: postmenopausal 1-10 years, osteopenia stage, regular resistance training feasible, normal kidney function
• Limited benefit: advanced osteoporosis, exercise difficulty, very advanced age (80+)
• Not recommended: chronic kidney disease, abnormal kidney function tests, complex multi-supplement/medication regimens

For women starting resistance training 5-10 years post-menopause, creatine 3-5g/day offers value as a stimulus amplifier. For advanced osteoporosis, pharmacology (bisphosphonates, denosumab) is first-line; creatine is an adjunct only.

Dose and form

Standard prescription.

• Dose: 3-5g/day (at 60kg body weight)
• Form: creatine monohydrate (thickest evidence). HCl or magnesium-bound forms are pricier but with thinner clinical data
• Timing: with meals (especially post-exercise meal). Fasted intake also works
• No loading needed: daily 5g reaches muscle saturation in about 4 weeks

Direct-import pricing in Korea: 10,000-20,000 KRW per month, among the cheapest evidence-backed supplements.

Side effects

Creatine ranks among the safest supplements but common early signals include.

• Weight gain 1-2kg (intramuscular water retention, not muscle gain)
• Mild gastrointestinal discomfort (resolved by split dosing)
• Transient nausea

The myth that creatine burdens kidneys persists, but adults with normal kidney function tolerate it safely. Discuss with a prescriber if chronic kidney disease is present.

Comparison with other menopausal nutrition options

For postmenopausal bone health.

• Calcium 1,000-1,200mg + vitamin D 800-1,000 IU: standard first-line, thick evidence.
• Vitamin K2 MK-7 100-180μg: prevents calcium artery deposition, evidence accumulating.
• Protein 1.2-1.6g/kg/day: required by both bone and muscle, dietary first.
• Magnesium 300-400mg: needed for vitamin D activation, supportive.
• Creatine 3-5g/day + exercise: additional stimulus to muscle and bone geometry, layer on after the above.

Creatine sits as adjunct, not first-line. After calcium, vitamin D, protein, and exercise are addressed, it offers an extra card for greater effect.

What’s next

The trend of creatine becoming a standard tool in women’s health is clear, but in the bone health domain it is being refined toward exercise-co-administration emphasis. Follow-up trials in 2026 are expected to add data separating exercise intensity, HRT co-administration effects, and benefits in 80+ populations. Korean menopause clinics are beginning to standardize creatine recommendations, with gynecology-rehabilitation co-management models taking shape.